Search Results - "Flowers, C"

Occurrence and removal of pharmaceuticals and personal care products (PPCPs) in an advanced wastewater reclamation plant by Yang, Xin, Flowers, Riley C., Weinberg, Howard S., Singer, Philip C.

“…The occurrence of nineteen pharmaceutically active compounds and personal care products was followed monthly for 12 months after various stages of treatment in…”
Get full text

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA by Omer, Saad B, Benjamin, Regina M, Brewer, Noel T, Buttenheim, Alison M, Callaghan, Timothy, Caplan, Arthur, Carpiano, Richard M, Clinton, Chelsea, DiResta, Renee, Elharake, Jad A, Flowers, Lisa C, Galvani, Alison P, Lakshmanan, Rekha, Maldonado, Yvonne A, McFadden, SarahAnn M, Mello, Michelle M, Opel, Douglas J, Reiss, Dorit R, Salmon, Daniel A, Schwartz, Jason L, Sharfstein, Joshua M, Hotez, Peter J

“…Since the first case of COVID-19 was identified in the USA in January, 2020, over 46 million people in the country have tested positive for SARS-CoV-2…”
Get full text

Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama by McKenna, Megan L, McAtee, Shannon, Bryan, Patricia E, Jeun, Rebecca, Ward, Tabitha, Kraus, Jacob, Bottazzi, Maria E, Hotez, Peter J, Flowers, Catherine C, Mejia, Rojelio

“…Hookworm infection affects 430 million people worldwide, causing iron deficiency, impaired cognitive development, and stunting in children. Because of the…”
Get full text

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy by Abramson, J.S., Feldman, T., Kroll-Desrosiers, A.R., Muffly, L.S., Winer, E., Flowers, C.R., Lansigan, F., Nabhan, C., Nastoupil, L.J., Nath, R., Goy, A., Castillo, J.J., Jagadeesh, D., Woda, B., Rosen, S.T., Smith, S.M., Evens, A.M.

“…Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear. We examined patient characteristics, treatment, and outcomes…”
Get full text

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials by Maurer, M.J., Habermann, T.M., Shi, Q., Schmitz, N., Cunningham, D., Pfreundschuh, M., Seymour, J.F., Jaeger, U., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Flowers, C.R., Coiffier, B.

“…Patients with diffuse large B-cell lymphoma treated with first-line anthracycline-based immunochemotherapy and remaining in remission at 2 years have excellent…”
Get full text

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study by de Vos, S., Swinnen, L.J., Wang, D., Reid, E., Fowler, N., Cordero, J., Dunbar, M., Enschede, S.H., Nolan, C., Petrich, A.M., Ross, J.A., Salem, A.H., Verdugo, M., Agarwal, S., Zhou, L., Kozloff, M., Nastoupil, L.J., Flowers, C.R.

“…Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic lymphocytic leukemia. We…”
Get full text

Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow by Greenwell, I. B., Flowers, C. R., Blum, K. A., Cohen, J. B.

“…Introduction: PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is…”
Get full text

Clinically significant liver injury in patients treated with natalizumab by BEZABEH, S., FLOWERS, C. M., KORTEPETER, C., AVIGAN, M.

“…Aliment Pharmacol Ther 31, 1028–1035 Summary Background  Natalizumab is a recombinant monoclonal antibody approved for the treatment of patients with multiple…”
Get full text

Pitfalls in the Diagnosis and Management of Hypercortisolism (Cushing Syndrome) in Humans; A Review of the Laboratory Medicine Perspective by Flowers, Kade C, Shipman, Kate E

“…Biochemical confirmation of a diagnosis of hypercortisolism (Cushing syndrome) is vital to direct further investigations, especially given the overlap with…”
Get full text

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices by Nooka, A.K., Nabhan, C., Zhou, X., Taylor, M.D., Byrtek, M., Miller, T.P., Friedberg, J.W., Zelenetz, A.D., Link, B.K., Cerhan, J.R., Dillon, H., Sinha, R., Shenoy, P.J., Levy, D., Dawson, K., Hirata, J.H., Flowers, C.R.

“…Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients…”
Get full text

Unmet needs in the first-line treatment of follicular lymphoma by Casulo, C., Nastoupil, L., Fowler, N.H., Friedberg, J.W., Flowers, C.R.

“…For the majority of patients with newly diagnosed follicular lymphoma (FL), current treatments, while not curative, allow for long remission durations…”
Get full text

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study by Chin, C. K., Lim, K. J., Lewis, K., Jain, P., Qing, Y., Feng, L., Cheah, C. Y., Seymour, J. F., Ritchie, D., Burbury, K., Tam, C. S., Fowler, N. H., Fayad, L. E., Westin, J. R., Neelapu, S. S., Hagemeister, F. B., Samaniego, F., Flowers, C. R., Nastoupil, L. J., Dickinson, M. J.

“…Summary High‐dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) are used as consolidation in first remission (CR1) in some centres for…”
Get full text

Science Visual Literacy: Learners' Perceptions and Knowledge of Diagrams by McTigue, Erin M., Flowers, Amanda C.

“…Constructing meaning from science texts relies not only on comprehending the words but also the diagrams and other graphics. The goal of this study was to…”
Get full text

Incentives for COVID-19 vaccination by Brewer, Noel T., Buttenheim, Alison M., Clinton, Chelsea V., Mello, Michelle M., Benjamin, Regina M., Callaghan, Timothy, Caplan, Arthur, Carpiano, Richard M., DiResta, Renee, Elharake, Jad A., Flowers, Lisa C., Galvani, Alison P., Hotez, Peter J., Lakshmanan, Rekha, Maldonado, Yvonne A., Omer, Saad B., Salmon, Daniel A., Schwartz, Jason L., Sharfstein, Joshua M., Opel, Douglas J.

Get full text

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype by Guo, X, Koff, J L, Moffitt, A B, Cinar, M, Ramachandiran, S, Chen, Z, Switchenko, J M, Mosunjac, M, Neill, S G, Mann, K P, Bagirov, M, Du, Y, Natkunam, Y, Khoury, H J, Rossi, M R, Harris, W, Flowers, C R, Lossos, I S, Boise, L H, Dave, S S, Kowalski, J, Bernal-Mizrachi, L

“…Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like…”
Get full text

Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell Lymphoma by Steiner, R. E., Strati, P., Flowers, C. R., Neelapu, S. S., Green, M., Nastoupil, L. J., Hagemeister, F. B., Feng, L., Ahmed, S., Nair, R., Fayad, L., Lee, H. J., Rodriguez, M. A., Westin, J. R.

Get full text

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL by Westin, J., Strati, P., Chihara, D., Pulsifer, B., Tom, J., Davis, R. E., Lee, H. J., Nair, R., Rodriguez, A., Hagemeister, F., Flowers, C., Nastoupil, L., Feng, L., Green, M., Fayad, L., Iyer, S., Ahmed, S., Steiner, R.

Get full text

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY by Herrera, A. F., Tracy, S., Sehn, L. H., Jardin, F., Lenz, G., Trněný, M., Salles, G., Flowers, C. R., Tilly, H., Sharman, J. P., Friedberg, J. W., Balasubramanian, S., Raghavan, V., Hirata, J., Lee, C., Jiang, Y., Morschhauser, F.

Get full text

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study by Casulo, C., Day, B., Dawson, K.L., Zhou, X., Flowers, C.R., Farber, C.M., Hainsworth, J.D., Cerhan, J.R., Link, B.K., Zelenetz, A.D., Friedberg, J.W.

“…Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma, with median age at diagnosis in the seventh decade. FL in young adults (YAs),…”
Get full text

Enacting Our Multidimensional Power: Black Women Sex Educators Demonstrate the Value of an Intersectional Sexuality Education Framework by Flowers, Sara C.

“…Historically, Black women have contributed to the foundations of medical research, gynecology, sexuality education, and sexual and reproductive justice, and…”
Get full text